Nanobiotix S.A.'s Revenue Takes a Hit, But Cash Runway Remains Strong

Nanobiotix S.A., a clinical-stage oncology company, reported revenue of EUR 5.6 million for the first half of 2026, down from EUR 26.4 million in the prior-year period.

The decline in revenue does not tell the full story, as Nanobiotix is valued on its development pipeline rather than near-term sales.

The company's central driver is JNJ-1900, a radioenhancer candidate being advanced with Johnson & Johnson. The key clinical program is NANORAY-312, a global Phase 3 trial in locally advanced head and neck cancer.

Nanobiotix reported a net loss of EUR 34.3 million for the first half of 2026, but its cash balance of EUR 110.9 million at June 30, 2026 is expected to fund operations into 2029.